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HIGHLIGHTS 
 Zebrafish-based in vivo assays are being popularized for anti(lymph)angiogenic 
drug screening.
 These assays show advantages when compared to chick or mouse-based models. 
 They contribute to speed up the screening and to reduce the number of sacrificed 
mice.
 They can provide relevant information regarding the mechanism of action and 
toxicity of the tested agents.
 Their use in the early phases of drug discovery may bias the mechanism of 
action of the hits identified, with a preferential selection of anti-VEGF agents.
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Teaser: In vivo assays that use the Tg(fli1a:EGFP)y1 transgenic zebrafish line are becoming 
increasingly popular to test anti(lymph)angiogenic drugs. Although their potential for drug 
discovery is unquestionable, their selection is biased.
2Abstract
Zebrafish, an amenable small teleost fish with a complex mammal-like circulatory system, is 
being increasingly employed for drug screening and toxicity studies. It combines the 
biological complexity of in vivo models with a much higher-throughput screening capability 
than those of other available animal models. Externally-growing transparent embryos, 
displaying well defined blood and lymphatic vessels, allow an inexpensive, rapid and 
automatable evaluation of drug candidates that are able to inhibit neovascularization. In this 
article, we briefly review zebrafish as a model for the screening of anti(lymph)angiogenic 
drugs, with emphasis on the advantages and limitations of the different zebrafish-based in 
vivo assays.  
3Angiogenesis, the formation of new blood vessels from pre-existing ones, is controlled by a 
sensitive interplay of stimulators and inhibitors. This tightly regulated process shows key 
roles in development and growth. In contrast, in adults it is only related to reproductive 
cycles, wound healing or bone repair. Nevertheless, a deregulated and persistent angiogenesis 
occurs in so-called angiogenesis-related diseases, such as proliferative retinopathies, 
psoriasis, rheumatoid arthritis, tumour growth or metastasis [1,2]. Angiogenesis is considered 
to be one of the hallmarks of cancer, where it plays a pivotal role in tumour progression and 
metastasis dissemination [3]. Therefore, targeting angiogenesis has attracted extensive 
attention in the field of pharmacological research in recent years. The search for new 
angiogenesis inhibitors is a hot topic, with hundreds of thousands of patients benefitting from 
their clinical use. Since bevacizumab, a humanized monoclonal antibody that blocks vascular 
endothelial growth factor A (VEGF), was approved for the treatment of metastatic colorectal 
cancer in 2004, a continuous increasing number of antiangiogenic therapies for cancer, 
virtually all of them blocking the activation of endothelial cells by VEGF, are gaining 
approval (see Table S1 in Supplementary material) [4]. Nevertheless, the limitations in the 
clinical success of anti-VEGF therapies, including intrinsic or acquired resistance appearance 
after months of treatment, indicates the need to search for new antiangiogenic drugs as well 
as new therapy strategies based on the combined targeting of different pathways in the 
tumour angiogenesis scenario [5].
Recently, the lymphatic system, which also plays a vital role in normal and pathological 
processes, has become a subject of great interest. In normal situations, the main functions of 
lymphatic vessels are: to collect the excess of protein-rich fluid that has been extravasated 
from blood vessels; to transport this fluid back into the blood circulation; and to absorb 
intestinal dietary fat and vitamins. The lymphatic system is also essential for the trafficking 
of immune cells and immune surveillance [6]. The formation of new lymphatic vessels, 
named lymphangiogenesis, is active during the embryonic development, but under adult 
physiological conditions this process is restricted to the endometrium during pregnancy. 
However, a defective or excessive lymphangiogenesis can lead to severe diseases involving 
lymph accumulation in tissues, dampened immune responses, connective tissue and fat 
accumulation, organ transplant rejection and cancer or metastatic dissemination [7,8].
Taking into account the role played by excessive angiogenesis and lymphangiogenesis in 
tumour growth and metastasis, as well as in other diseases, the identification of new drugs 
4that are able to inhibit these processes remains an urgent need. For this purpose, the 
development of new reliable and accurate in vitro, and especially, in vivo models, is 
demanded. Currently, different in vitro, ex vivo and in vivo systems are being applied to the 
screening and characterization of new lymph/angiomodulators. All these different models 
have their own advantages and disadvantages, their combination being mandatory to get 
insight on the impact of a given compound in the global process, therefore increasing the 
chances of success in preclinical and clinical development. In general, in vitro assays of 
angiogenesis (reviewed in [9]) offer information about the endothelial cell behaviour under 
drug exposure, but they do not consider the entire microenvironment. Ex vivo angiogenesis 
assays include the mouse or rat aortic ring, the lymphatic ring and the retinal explant assays, 
among others. These ex vivo assays are useful to analyse vessel sprouting from vascular 
explants, although they do not allow the study of the circulating endothelial progenitors 
recruited in the angiogenic process or the hemodynamic forces that play a relevant role in 
angiogenesis, vascular remodelling and maturation [10]. In contrast, in vivo models reproduce 
the cellular and molecular features involving the complete process of new vessel formation 
and the effect of modulators in the whole organism, giving a more complete overview about 
the putative effect of the studied drug, when comparing with in vitro assays. However, a 
combination of cell-based and organism-based chemical screens can complement each other, 
and eventually provide additional information. Traditionally, antiangiogenic compounds have 
been tested in vivo by means of either the chick chorioallantoic membrane (CAM) [11], or by 
several mouse models, including the Matrigel plug, sponge implant and disc assays, among 
others [12]. Moreover, in previous years zebrafish embryo has emerged as a promising in 
vivo model that can throw light on the biology of physiological and tumour angiogenesis at 
the whole organism level, allowing a cost-effective high throughput chemical screening. 
Interestingly, there is evidence revealing that drug targets are well conserved between 
zebrafish and humans. Therefore, lead compounds identified in zebrafish-based chemical 
screens are likely to have similar activities in humans [13]. In Table 1, the main strengths and 
weaknesses of the use of chick, mouse or zebrafish in vivo models to assay angiogenesis are 
listed. Among the strengths of zebrafish embryo-based in vivo assays are the simple 
manipulation, economy of the tested agents, which can be assayed at a known concentration, 
and the possibility to obtain relevant quantitative information in a short time. The absorption 
and bioavailability of a compound in these lower vertebrate animal models depend on its 
molecular weight, hydrophobicity, and number of hydrogen bond donors and acceptors [14], 
although solubilizing agents like dimethyl sulfoxide (DMSO) can be added to the screening 
5media to ensure solubility and drug penetration. Furthermore, zebrafish embryos are 
generally permeable to small molecules dissolved in the swimming medium, allowing drug 
administration by immersion. However, the drug concentration for waterborne treatment of 
zebrafish embryos has usually to be increased by an order of magnitude above the effective 
concentrations required for cell culture experiments. The use of zebrafish embryos facilitates 
the performance of the high number of experiments needed either for statistical calculations 
or for high throughput screening. Moreover, the availability of very diverse molecular tools 
and transgenic zebrafish lines may give clues for the mechanism of action and the therapeutic 
window of the drug candidates. Although the results obtained with zebrafish models would 
have to be finally confirmed in a mammalian system (usually, a murine-based one), the 
incorporation of zebrafish in vivo assays in the drug discovery way seems to be a logical 
option to speed up the screening process and to reduce the number of mice sacrificed. The 
advantages of zebrafish embryo models may explain the observed increased popularity of 
zebrafish-based angiogenesis assays. In the last fifteen years, an outstanding inflation of 
articles dealing with (lymph)angiogenesis can be found in scientific literature. Bibliometric 
search in Scopus or PubMed using combinations of terms, such as <<angiogenesis>> and 
each model species including humans, provide data to follow a rise and fall trend in the field. 
After a constant increase for more than ten years, an important recent decay in the relative 
number of published angiogenesis studies in all species, including humans, is indeed found, 
potentially due to the global economic crisis. During this period, zebrafish studies are unique 
as they show a stable maintenance in both general scientific production and that on 
angiogenesis in particular (see Figure S1 in Supplementary material). Further bibliometric 
analyses of this phenomenon support the view that development of new antiangiogenic drugs 
using transgenic zebrafish in vivo assays is at the heart of this statistical behaviour. In this 
review, we focus our attention on this effect trying to highlight underlying experimental 
reasons.
Zebrafish-based in vivo angiogenesis assays
Zebrafish have a closed circulatory system. The molecular processes underlying their vessel 
formation, the anatomic mechanisms for the developing vasculature and the process used to 
assemble vessels, are highly similar to those occurring in humans [15]. Importantly, early 
hematopoietic and endothelial cells in mammals and zebrafish express a common set of genes 
[16]. Early zebrafish embryonic vascular development begins at around 12 hour-post-
6fertilization (hpf), when angioblasts originate in the lateral plate mesoderm. Later at around 
24 hpf the development of dorsal aorta (DA) and dorsal vein (DV) forms the first circulation 
loop [17]. Once the primitive zebrafish vasculature is formed by vasculogenesis, most of the 
subsequent vessels, including the development of intersegmental vessels (ISV, blood vessels 
in between each two neighbouring myomeres) and sub-intestinal veins (SIV), occur by 
angiogenesis [18]. Thus, for the formation of the ISV a set of new sprouts emerges from the 
dorsal part of the DA and grows dorsally along vertical somite boundaries to interconnect and 
form the dorsal longitudinal anastomotic vessel (DLAV) [13]. On the other hand, SIV are 
originated from the posterior cardinal vein (PCV) and developed later than the ISV (between 
48 and 72 hpf, Figure 1A) [19]. Nonetheless, it is worth mentioning that ECs in different 
vascular beds use different molecular cues and morphogenetic mechanisms to form the 
vessels. Detailed information on the complex regulatory signalling pathways involved in 
zebrafish angiogenesis is provided in Supplementary material.
The scientific community is paying increasing attention to several transgenic zebrafish lines 
as in vivo live fluorescent models for the study of angiogenesis modulation [20]. The ability 
to produce tissue-specific germ line transgenic fish expressing enhanced green fluorescent 
protein (EGFP) has made this organism an ideal system to visualize the formation of 
embryonic and adult structures. Tg(fli1a:EGFP)y1 is a popular transgene in zebrafish that 
drives EGFP expression under endothelium-specific fli1a promoter. This promoter is 
specifically activated in endothelial cells along the complete zebrafish embryo, juvenile and 
adult (see Figure 1A-B). This specific expression leads to green in vivo fluorescence in all 
endothelial cells (see also Figure S2 in Supplementary material). This permits observation of 
bright blood and lymphatic vessels at all stages of embryogenesis (see Figure S2 B-E in 
Supplementary material). During late development and in adult specimens, EGFP is also 
observed in transparent organs, such as the fins (see Figure S2 F-G in Supplementary 
material). In embryos, ISV, SIV, the supra-intestinal artery (SIA), and the hyaloid vessels 
over the ocular lenses have been used to evaluate angiogenesis inhibition or promotion by 
chemical reagents added to water [21,22]. Thoracic duct formation (see Figure S2 D-E in 
Supplementary material) has also been used to study the effect of compounds over 
lymphangiogenesis during transgenic zebrafish embryogenesis [23]. This will be further 
discussed below in the section "Zebrafish as a tool for studying lymphangiogenesis". On the 
other hand, new vessels associated with the outgrowing blastema can also be observed during 
the regeneration of the fin induced after cutting. This regeneration process, that has been 
7classically studied to analyse organ morphogenesis [24], has also been used in biomedical 
[25,26] or toxicology studies [27] induced after fin clips in embryos [28], larvae [29] and 
adults (see Figure S2 F-G in Supplementary material). These studies have been successfully 
used to establish the importance of VEGFR in this regeneration process, allowing the 
detection of chemical agents that are able to inhibit regenerative angiogenesis [30].
Although many other alternative endothelial-driven transgenic lines have been produced, the 
most frequently used one is Tg(fli1a:EGFP)y1, accounting for more than 85% of total 
citations. Table S2 (Supplementary material) lists the most popular available endothelial-
driven transgenic lines, with indication of their gene expression, the number of research 
articles citing them at ZFIN, suppliers and references. 
Comparison of the different zebrafish-based assays for the screening of 
antiangiogenic drugs 
As mentioned above, different approaches are being used in the screening of antiangiogenic 
compounds in zebrafish models. They include the intersegmental vessel (ISV) formation, the 
development of subintestinal vessels (SIV), the thoracic duct formation (TDF) assay, the 
adult caudal fin regeneration (ACFR) test, the hyaloid vessels (HV) formation assay, the 
blood flux videos, the central nervous system (CNS) vascular development assays, the 
tumour-xenograft-induced angiogenesis assays, the retinal angiogenesis assays in hypoxia-
exposed adult zebrafish and the coronary angiogenesis assay upon cardiac amputation or 
cryoinjury in adults. A literature review of the published articles that used any of those 
models to test the activity of antiangiogenic drugs reveals that ISV is largely the most widely 
used zebrafish-based in vivo assay, followed by SIV and ACFR assays (see histogram in 
Figure 1C). Reasons for the prevalence of ISV use include the easy-handling, fastness and 
economy of the tested agent, since it is performed in small volumes [31]. The use of 
transparent embryos facilitates the visualization of the drug effect and allows an easy 
automatization, so that in a few days a number of embryos can be treated, yielding abounding 
results in a short time [20,32]. A high content screening assay [33] and a high throughput 
strategy [34] are good examples of this extensive attempt to establish an efficient drug 
pipeline using zebrafish.  
Among the limitations of ISV assay, the possible false positive results arising from an effect 
on embryo development rather than on angiogenesis inhibition should be considered. This 
8limitation could be somehow superseded by complementing this assay with the information 
obtained by recording the blood flux in short videos (see Supplementary videos S1-S7 in 
Supplementary material). Sometimes, drugs do not inhibit vessel formation, but blood 
circulation through ISV is compromised or abolished. These effects on blood circulation are 
easily observed in the videos. The number of odd results can also be minimized by using the 
ACFR assay, from which clear conclusions are normally derived (see Figure S3 and Table S3 
in Supplementary material). Furthermore, this assay provides a better approximation to the 
toxicity of tested reagents, with lower effective doses being needed [30]. A limitation of 
ACFR assay relies on the need of higher amounts of the tested agents, derived from the use 
of larger working volumes. This would be partially overridden by the use of young zebrafish, 
which could be assayed in smaller volumes. Moreover, the interruption of the fin 
regeneration by potential antiangiogenic drugs could be caused by a direct teratogenic effect 
of the reagent over osteoblasts [35]. Alternative wound healing assays are being proposed 
in embryos [36] and adults (MMB, manuscript in preparation) to discriminate between 
these potential effects of reagents. Table S4 in Supplementary material summarizes the 
advantages and disadvantages observed in the three different zebrafish angiogenesis assays 
herein discussed, namely, the ISV assay, the video visualization of blood flux through ISV 
and the ACFR assay.
A comment regarding the sensitive zebrafish embryo retina neovascularization assays 
deserves to be underscored. Inhibitors of angiogenesis are here to stay for the therapy of 
irreversible causes of blindness such as macular degeneration, macular edema and some 
retinopathies [37]. Although at present anti-VEGF therapies are the standard of care for some 
of these diseases, the results obtained are far from perfect, the development of new 
antiangiogenic drugs being an urgent need also in ophthalmology. Consequently, zebrafish 
embryos may be used as a novel and cost-effective tool for the screening of antiangiogenic 
drugs for the eye [38-40]. Despite the anatomical and developmental differences between 
ocular vasculatures in teleosts and humans, most of the pathologies related to a deregulated 
ocular angiogenesis share common molecular and cellular mechanisms [41]. Indeed, several 
models of vascular ocular disorders (retinopathies and macular degeneration, among others) 
have been developed using zebrafish embryos and is widely accepted that eye 
neovascularization in zebrafish embryos may represent a novel target for the identification of 
new angiogenesis inhibitors [38,42]. 
The table within Figure 2 shows the information regarding the antiangiogenic activity 
9exhibited by several inhibitors of angiogenesis when these zebrafish assays were applied 
(Figure S4 in Supplementary material and the accompanying reference list is a version of 
Figure 2 including the bibliographic references). They have been gathered from a 
bibliography survey as well as from some of our own results, also shown in Figure S3 
(Supplementary information).  Data of in vivo activity in chick or mouse-models have also 
been included, when available. Some interesting conclusions can be extracted from the 
contents of Table 2. Firstly, ISV and SIV assays yield similar results for all the tested agents, 
in terms of angiogenesis inhibition. This could facilitate the interlab comparison, since the 
choice of one or another assay may largely depend on the researcher’s skills and preferences. 
Secondly, this model emerges as an excellent tool for the screening of VEGF/VEGFR 
inhibitors, easily detected by any of the zebrafish-based assays (with the exception of the 
human antibody bevacizumab, by a limitation of interspecies recognition of the zebrafish 
VEGF). Moreover, this homogeneity of results could help to decipher these drugs mode of 
action and to resolve an effective pipeline for an ever-increasing number of agents, some of 
them already reaching full approval or advanced clinical trials. Taking this into account, it 
has been suggested that comparison of the susceptibility of embryonic and adult zebrafish 
angiogenesis to a given VEGFR inhibitor could provide an indication of the drug selectivity 
[30]. Furthermore, comparison of the effect of compounds on angiogenesis and toxicity 
parameters in zebrafish embryos, in an efficacy-toxicity approach, may help to stratify 
antiangiogenic drug candidates based on their action mechanism, estimate their therapeutic 
window, and establish a prediction of their possible clinical outcome [43].
Data from Table within Figure 2 (Figure 2A) show a clear bias in the results obtained by 
using zebrafish-based assays, given that they do not appear to allow the detection of agents 
acting on some non-VEGF targets. It should be kept in mind that limitations of clinical anti-
VEGF trials, including moderate benefits, or the appearance of toxicity or resistance 
mechanisms could be overcome by compounds targeting alternative angiogenic pathways, 
which could prolong the duration of anti-VEGF treatments and extend their clinical benefits 
[44]. This bias, perceived as a limitation of these zebrafish-based assays, has been observed 
in the case of erlotinib (EGFR inhibitor, approved by FDA for the treatment of non-small cell 
lung cancer), CAS 948557-43-5 (a Tie 2 kinase inhibitor), aeroplysinin-1 (a sponge derived 
compound that inhibits the angiogenic activation downstream the receptor), paclitaxel (a 
cytoskeletal drug that targets tubulin) and the endothelial proliferation inhibitors targeting 
methionine-aminopeptidase 2 (MetAP2) fumagillin and TNP470, among others. However, all 
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these compounds can be readily identified with chick or mouse-based assays. This bias is 
probably due to the preponderance of VEGF signalling in the control of zebrafish 
developmental and regenerative angiogenesis (Figure 2B) [45]. The case of FGF inhibitors 
deserves a special mention, since they seem to be detected by means of the ACFR, but not by 
the ISV or SIV assays (Figure 2B). This may be explained by the relevant role played by 
FGF in the regenerative angiogenesis after amputation (Figure 2B) [46]. Something similar 
occurs with genistein and LY294002, inhibitors of PI3K that can inhibit, at least partially, 
angiogenesis in regenerating fin or hyaloid angiogenesis, but not ISV (Figure 2B) [39,47]. 
This is in agreement with the importance of PI3K/AKT/mammalian target of rapamycin 
(mTOR) signalling pathway in ocular neovascularization and fin regeneration [47,48]. All 
these commented data show that like Janus, the ancient Roman god of duality, the zebrafish-
based in vivo assays have two faces: one looking towards an effective, fast and easy tool for 
the selection of new antiangiogenic drugs, and the other looking to those other missed 
compound that could help to increase the clinical efficacy of the anti-VEGF therapies. In 
other words, although zebrafish is an attractive tool for the drug discovery, it has some 
limitations related with the detection of other non-VEGF targeted compounds, which could 
help to overcome the problems of toxicity or resistance mechanisms already seen with anti-
VEGF treatments [44]. 
Zebrafish for the screening of antilymphangiogenic drugs
The role of the lymphatic vessels in different human pathological conditions has already been 
well documented and recently reviewed [49]. This will be further discussed below in the 
section "The role of lymphatic vessels in human diseases" (Supplementary material). In the 
past, the understanding of biological and functional aspects of the human lymphatic system in 
health and disease has been overshadowed by the enormous emphasis and progress obtained 
on angiogenesis. This fact has been partly due to the difficulties found in the identification of 
these translucent vessels in tissues, mainly because of the lack of well-defined lineage-
specific markers. Recently this scenario has rapidly changed with the discovery of useful 
transcription factors and proteins expressed by lymphatic endothelial cells (LECs), such as 
Prox-1, podoplanin, LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1) and 
VEGFR-3 [50]. Furthermore, advances in imaging technologies together with the new 
molecular tools and genetics models have contributed to accelerate the pace of lymphatic 
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system research.
Zebrafish embryo is becoming an emerging and fascinating model to facilitate the progress 
on the lymphangiogenesis field and to provide a powerful tool for the screening of 
lymphangiogenic antagonists/agonists [51]. Zebrafish embryo lymphatic vascular system 
shares molecular, morphological and functional characteristics with the lymphatic vessels 
present in higher vertebrates [15]. Lymphatic development starts after the establishment of a 
functional cardiovascular system, when LEC progenitors appear to originate from the 
cardinal vein (2 dpf) [52]. At this stage, jugular lymphatic sacs originate rostral lymphatic 
vessels and sprouts forming the parachordal vessels emerge from the PCV. Then, the arterial 
intersegmental vessels serve as guidance routes for the dorsal and ventral navigation of 
lymphatic progenitors, which form the rest of the trunk lymphatic network, including the 
dorsal longitudinal lymphatic vessel, the intersegmental lymphatic vessels and the thoracic 
duct. Around 3.5-4 dpf, the formation of the thoracic duct takes place by lymphangiogenesis 
when ventrally-migrating LECs branch rostrally and caudally between the DA and PCV, and 
finally this duct expands and forms lymph sacs at later stages [53]. Detailed information on 
the complex regulatory signalling pathways involved in zebrafish lymphangiogenesis is 
provided in Supplementary material.
One of the advantages offered by zebrafish embryo as a model to study lymphangiogenesis is 
the possibility of applying a modified version of the lymphangiography, the traditional 
method used in humans to visualize the lymphatic vasculature. It is worth mentioning that in 
this technique, fluorescent spheres conjugated with high molecular weight particles are 
injected subcutaneously into the tail region or directly into the thoracic duct, allowing the 
rapid detection of structural aberrations in the lymphatic vessels upon drug treatment. 
Nonetheless, these methods are considered too complex to be included in a drug screening 
platform and currently, the most promising strategy is the use of transgenic zebrafish. Indeed, 
as mentioned in the introduction, several zebrafish transgenic lines that express fluorescent 
reporters under vascular specific promoters have been instrumental in making zebrafish a 
favourite model for in vivo screening and functional analysis of the vascular system. In 
addition, there are available transgenic lines with specific expression in lymphatic vessels 
that facilitate the visualization of the lymphatic system for scientists [54]. See the 
Supplementary material section "Transgenic zebrafish lines available to study 
lymphangiogenesis" for additional details on this issue.
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The use of zebrafish embryo models for studying lymphangiogenesis primarily focuses on the 
thoracic duct development, which can be quantified by counting the number of somites with 
thoracic duct or parachordal lymphangioblasts. Results can be represented as the developed 
or inhibited thoracic duct length. Another approach (used with transgenic lines that express 
nuclear fluorophores under the fli1a promoter) is the direct counting of LECs within the 
zebrafish thoracic duct. Although the thoracic duct is regarded as the common site, additional 
lymphatic vessels, including a complex network of blind-ended lymphatic capillaries, can be 
identified in the zebrafish trunk using lymphangiography [53].
Zebrafish embryo phenotype-based chemical screening has been used to identify the 
antilymphangiogenic properties of different drugs previously approved for human use [55]. In 
this chemical battery, kaempferol, cinnarizine, flunarizine and leflunomide have shown anti-
lymphatic activity by inhibiting the thoracic duct formation in zebrafish [55]. They confirmed 
their data in a murine in vivo lymphangiogenesis Matrigel plug assay, in which kaempferol, 
leflunomide and flunarizine prevented lymphatic growth. On the other hand, zebrafish 
exposed to MAZ51 (VEGFR-3 inhibitor) have shown a significant reduction in the number of 
lymphatic capillaries [56], and rapamycin (antiproliferative compound) has suppressed the 
thoracic duct development in zebrafish [57]. Other experiments have revealed that CI-1040 
(MAPK inhibitor), BEZ235 (dual PI3K and TOR inhibitor) and PTK787/ZK222584 
(VEGFR-1,-2,-3 inhibitor) impaired thoracic duct formation in zebrafish [58]. Interestingly, 
our research using the zebrafish as a tool for lymphangiogenesis analysis has shown that 
bathing exposure with toluquinol and AD0157, two marine-derived compounds, reduces the 
thoracic duct formation in zebrafish embryos. These compounds have shown anti-
lymphangiogenic properties in a wide experimental battery of in vitro, ex vivo and in vivo 
models [23,59]. Figure 3 shows the use of the zebrafish thoracic duct lymphangiogenesis 
assay to identify toluquinol as an antilymphangiogenic compound.
Nonetheless, as can be noticed in this review, the use of zebrafish embryo as a model to 
search for new lymphangiogenesis inhibitors is still far from its use in the antiangiogenic 
drugs screening. 
In spite of the potential of the zebrafish model as an attractive approach for the identification 
of anti(lymph)angiogenic drugs, this model has a number of limitations, recently reviewed 
[60]. Therefore, the combination of different in vivo models in order to get insight into the 
properties and action mechanisms of new potential anti(lymph)angiogenic drugs is highly 
recommended. In this context, mouse and zebrafish embryo can be considered as 
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complementary models for the study of lymphangiogenesis and lymphatic vessel-related 
diseases [53].
Concluding remarks
In general, the efficacy of specific chemicals in in vitro assays is far away from optimal when 
compared to their clinical use. This type of bias might be related to either the potentiality of 
treatment (in vivo assays are far more complex than in vitro ones), or particularities in the 
effective concentration in the final preclinical assays. In this cell transition between cell 
culture and higher vertebrate in vivo assays, zebrafish-based assays appear to be potentially 
useful, given their advantages as compared to chick and mouse-based models. Data available 
in bibliography, including our own research, show that zebrafish provides effective 
experimental models not only for anti(lymph)angiogenic drug screening but also for drug 
pharmacological characterization and optimization. Zebrafish angiograms, both in embryos 
and adults, are easy-handling assay procedures that may permit scientist to analyse hundreds 
of compounds in a short time, which is essential for a high throughput screening. Moreover, 
besides the different effects of those compounds on (lymph)angiogenesis, the zebrafish 
embryo assays allow the identification of side effects, including toxicity, developmental 
delay, tissue malformations or brain haemorrhage, and provide a valuable prediction of the 
therapeutic window of the new drug candidates. The combination of the information derived 
from the in vitro, ex vivo and in vivo assays will help to better evaluate the pharmacological 
potential of the new anti(lymph)angiogenic agents, therefore increasing the chances to 
succeed in preclinical and clinical trials.  
A final reflection on drawbacks in zebrafish assays in the early steps of drug discovery 
should be added. When “fishing” new drug candidates by means of blind screening strategies, 
guided by activity assays, the size of the mesh will determine the size of the fish caught in the 
net.  Concern that zebrafish-based in vivo assays could induce a bias in the action mechanism 
of the hits selected, probably discarding compounds that could inhibit angiogenesis by acting 
on non-VEGF relevant targets, should be kept in mind. In any case, as stated in the old Irish 
saying ‘May the holes in your net be no larger than the fish in it’, evidence that zebrafish is 
an excellent system to easily identify new anti-VEGF agents and the fact that virtually all the 
approved antiangiogenic therapies target VEGF, ensure the zebrafish-based in vivo assay 
application in several steps of the drug discovery process.  
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Figure legends
Figure 1. Tg(fli1a:EGFP)y1/AB zebrafish in vivo assays to screen (lymph)angiogenic 
modulators. 
(A) Scheme of a 48 hpf embryo showing in vivo assays. Green lines are transgenic 
endothelial cells. Red rectangle shows the region observed in the right fluorescence 
figure. Vertical discontinuous line is caudal fin cut section. Bar is 1 mm. CNV, TX, PAC, 
SIV, DA, DLAV, ISV and PCV are central nervous system, tumour xenograft assays, 
parachordal vessels, subintestinal vessels, dorsal aorta, dorsal longitudinal anastomosis 
vessels, intersegmental vessels and posterior cardinal vein, respectively. (B) Scheme of an 
adult zebrafish with regenerating caudal fin. Grey arrow shows fluorescence image of 
regenerating vessels in the caudal fin blastema (right of fin cut white discontinuous line). 
RV and CV represent retinal and coronary vessels (C) Histogram showing number of 
reviewed articles using zebrafish in vivo assays described in the main text. A complete list 
of the bibliographic references used to build the histogram is provided in Supplementary 
material.
Figure 2. Comparison of the activity of angiogenesis inhibitors demonstrated by 
using different in vivo assays. 
(A) Table showing the information regarding the antiangiogenic activity exhibited by 
several inhibitors of angiogenesis when these in vivo assays were applied (A version of 
this table including the bibliographic references is available in Supplementary material). 
They have been gathered from a bibliography survey as well as from some of our own 
results, also shown in Figure S3 (Supplementary information). Colour code: brown: 
negative; pale brown: very moderate; green: positive; pale green: partial inhibition. (B) 
Scheme summarizing the results presented in the upper table. A free arrow indicates that 
compounds acting on a given target show a positive inhibition in a particular zebrafish-
based in vivo assay. A crossed arrow indicates that no antiangiogenic activity is detected 
by means of that assay. 
Figure 3. Toluquinol abolishes thoracic duct development in the lymphangiogenesis 
zebrafish assay. 
Transgenic Tg(fli1:eGFP)y1 zebrafish embryos were incubated in zebrafish water with 
the indicated concentrations of the tested compound at 28.5 °C for 4 days and then, 
thoracic duct length was analysed in the anesthetized embryos. (A) Representatives 
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pictures of untreated and treated zebrafish. White arrowheads indicate the thoracic duct in 
zebrafish and the red square includes the area at higher magnification (bar=100 μm and 
70 μm on higher magnification). (B) Quantification of the defective thoracic duct 
formation at 5 dpf determined by the percentages of embryos with severe (no vessels), 
drastic (5-25% of TD), moderate (25-90% of TD) and no lymphatic defects (100% of 
TD). A total of 50 embryos were analysed in each experimental condition.



Table 1. Strengths and weaknesses of the major model species used to evaluate antiangiogenic drugs in vivo
Model species
(Typical assays)
Strengths Weaknesses
Chick
(CAM)
 Inexpensive
 Suitable for medium-scale screening
 Simple manipulation
 Low to moderate amounts of test agents are required
 Non-mammalian: results must be validated in mammalian 
systems for potential clinical application
 Embryonic
 Difficult to be evaluated (the use of at least two blind 
evaluators is advisable)
 Nonspecific inflammatory reaction may appear
 Unavailable tools to characterize molecular mechanism 
 Actual concentrations of the test compounds depend on 
the diffusion from the disc
Mouse
(Matrigel plug, 
sponge, corneal 
micropocket, 
disc assay…)
 Mammalian
 Tools to characterize molecular mechanism are available
 Some of them permit long-term monitoring
 Quantitative assays
 Expensive
 Time consuming
 Ethically questionable in occasions
 Technically demanding
 Higher amounts of test agents are required
 Non suitable for primary assay in medium to large-scale 
screening
Zebrafish
(ISV, SIV, caudal fin 
regeneration…)
 Tools to characterize molecular mechanism are available
 Quantitative
 Fast
 Suitable for high throughput screening
 Automated in 96 well plates
 Simple manipulation
 Many transgenic zebrafish lines are available
 Small amounts of test agents are required
 Statistically significant numbers of embryos can be used 
for each assay
 Real concentrations of the test compounds are known
 Yields useful information regarding pharmacological 
profile and toxicity of the test agents (therapeutic 
windows)
 Non-mammalian: results must be validated in mammalian 
systems for potential clinical application
 Embryonic (mostly)
 The small size of embryos can make some observation 
challenging
 Specialized breeding conditions are required
 Caudal fin amputation studies require higher working 
volumes and therefore higher amounts of test agents
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Angiogenesis and lymphangiogenesis signalling and regulation in zebrafish 
Angiogenesis signalling 
Early expression of stem cell leukemia (scl) and fetal liver kinase-1/vascular endothelial 
growth factor receptor 2 (flk1/vegfr2) is required for endothelial and hematopoietic 
lineage formation in both mouse and zebrafish [1,2]. It has also been reported that ETS 
factors function synergistically with other factors, including members of the Forkhead 
(FOX) family of transcription factors [3] and KLF genes [3,4] to specify endothelial cell 
fate.  
Ephrin B2 is expressed in arterial endothelial cells although absent in veins, and its 
receptor EphB4, is mainly expressed in venous endothelial cells [5]. Likewise, sonic 
hedgehog (shh) induces the expression of vegf, and the VEGF-VEGFR2/Nrp1 pathway 
activates Notch signalling (Notch, Delta, Jagged, etc.) during arterial specification [6,7]. 
Phospholipase C (PLC)-γ1, an immediate downstream component of the VEGF 
receptors, is required for transducing VEGF signalling [8,9], while COUP-TFII is 
required for venous differentiation [10]. Interestingly, selective cell segregation is 
controlled by different signalling pathways, including VEGF-A and VEGF-C [5]. 
Moreover, the phosphoinositide 3-kinase (PI3K) and the extracellular signal-regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK) signalling pathways, 
antagonistically regulate arterial-venous fate determination during zebrafish 
development [11-13], and Dep1 acts upstream of PI3K in the arterial differentiation 
[14]. In addition, lack of Sox7/18 in zebrafish results in loss of arteries, showing that are 
important actors in the arterial-venous morphogenesis [15-17]. 
Several studies have shown that VEGF-A is produced by the somites among which the 
ISV sprouts migrate, and VEGF-A/VEGFR-2, as well as Notch and 
Semaphorin/PlexinD1 signalling pathways, promote the growth of these ISV [18-20]. 
The inhibition of ISV formation upon VEGFR-2 function loss confirms its critical role 
in this process [19]. Of note, the VEGFR-1 receptor also plays a crucial role during 
angiogenesis in zebrafish [21]. Specification of tip and stalk cells in these sprouts is 
controlled by the mentioned signalling cascades [22]. On the other hand, SIV are 
originated from the PCV and developed later than the ISV (around 30 hpf) [23]. 
Nonetheless, it is worth mentioning that ECs in different vascular beds use different 
molecular cues and morphogenetic mechanisms to form the vessels. For instance, the 
BMP signalling pathway is the major player in the initial stage of the subintestinal 
plexus formation, although Notch, VEGF and Semaphorin/PlexinD1 signallings are 
required for proper formation of functional arterial SIVs. Flt1 participates as well in the 
remodeling of the subintestinal plexus, involving retraction of venous leading buds [24]. 
In conclusion, angiogenic factors mediating ISV development such as PDGFs and SHH 
are not required for SIV development, whereas BMP are required for SIV but not for 
ISV. 
Interestingly, the Msx and BMP genes are activated in the zebrafish caudal fin 
regeneration [25]. Tail fin vessel regeneration is sensitive to VEGFR inhibition and 
several molecular markers have been identified in this process, including the 
transcription factor msxb, the fibroblast growth factor receptor 1, FGFR-1 as well as the 
SHH [26]. 
Although the aforementioned molecules and signalling cascades are the most relevant in 
the angiogenic process in zebrafish, others such as survivin and Nogo-B have been 
recently described as angiogenesis regulators [27-30]. 
 
 
Lymphangiogenesis signalling 
Prox1 is a master regulator in the lymphatic specification from a subpopulation of 
zebrafish PCV endothelial cells, and VEGFC-VEGFR3 signalling is also likely to 
induce budding and migration of the Prox1-postive secondary sprouting cells in 
zebrafish [31]. However, it is also possible a contribution to lymphatic progenitors 
from mesenchyme [32]. In the embryonic zebrafish, LECs express Neuropilin-2 [33] 
and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) [34], and in the 
adult stage, angiopoietin 2 is expressed in those lymphatic vessels as well [35]. Up to 
now several signalling pathway has been described to modulate the lymphatic 
development [36], although VEGF-C appears to be the main chemoattractant cue for 
migrating LECs [37] through the VEGFR-3 cascade activation. Other signalling 
cascades, such as G Protein Coupled Receptor and BMP/TGFβ signalling, and Notch 
pathways are known to modulate distinct aspects of lymphatic development [38]. 
Furthermore, VEGF-D, cooperatively with VEGF-C, Alk3/Alk3b, Smad5 and Apelin 
regulates lymphangiogenesis during zebrafish embryonic development [39-41]. 
 
 
The role of lymphatic vessels in human diseases 
Lymphedema, characterized by the presence of localized fluid retention and excessive 
tissue swelling caused by a compromised/damaged lymphatic system unable to return 
interstitial fluid to the thoracic duct and bloodstream, affects 100 million people around 
the world [42]. On the other hand, human lymphatic syndromes, such as Milroy disease 
(a congenital form of lymphedema), lymphedemadistichiasis syndrome (LDS) 
(lymphedema onset at adolescence) and Hennekam syndrome (a generalized lymphatic 
dysplasia) are caused by mutations in crucial players of the lymphatic vasculature 
(VEGFR-3 FOXC2 and CCBE1, respectively) [43-45]. Crohn’s disease and ulcerative 
colitis, the two most commonly occurring inflammatory bowel diseases (IBDs) are 
developed when intestinal lymphatics are obstructed due to the lymphoid aggregates 
formation [46]. Moreover, the lymphatic vasculature may have a potential role in 
guarding cardiovascular health by facilitating the proper excretion of cholesterol from 
the extravascular tissues and avoiding atherosclerosis [47].  
Metastatic dissemination of tumor cells can occur via lymphatics, especially in breast, 
colon, prostate and melanoma cancer [48-49]. Importantly, the presence of metastatic 
cells in lymph nodes indicates bad prognosis for patients since tumors cells from 
primary solid tumors are gaining access to the lymphatic vessels, invading lymph nodes 
and they can spread to distant organs [50,51].  
Considering the increasing number of human lymphangiogenesis-related disorders is 
not surprising that many investigations are focusing on this topic. Numerous efforts are 
being made to find effective therapeutic strategies based on the identification and 
characterization of new and promising antilymphangiogenic drugs [49,52]. 
Additionally, the screening and discovery of potent lymphangiogenesis modulators is 
regarded as a new strategy to overcome the development of drug resistence frequently 
seen in the treatment with antitumor-associated angiogenesis compounds [20]. Given 
the complexity and redundancy of the VEGF signalling network in promoting 
angiogenesis and lymphangiogenesis the blockade of either VEGFR-3 or VEGFR-2 
alone might not be sufficient and, multitargeting by small molecules may be an 
appropriate strategy for effective inhibition of (lymph)angiogenesis [20].  
Although the FDA has clinically approved different multi-kinase inhibitors, such as 
sunitinib, that also target the lymphangiogenic process, there are not approved therapies 
specifically targeting lymphangiogenesis [49,53]. Some antilymphangiogenic drugs 
(monoclonal antibodies VGX-100 and IMC-3C5) have undergone phase I clinical trials 
for advanced and metastatic solid tumors [54,55], and some others are under preclinical 
trials.  
 
Transgenic zebrafish lines available to study lymphangiogenesis 
Currently, there is a number of transgenic zebrafish lines available to study 
lymphangiogenesis. Among these transgenic lines, is worth to mention the 
Tg(fli1a:egfp)y1, with expression in both lymphatic and blood vessels, with non-
vascular expression in neural crest derived tissues in the head) [7]; the 
Tg(stab1BAC:yfp), with weak expression in veins and lymphatics [31]; 
Tg(sagff27c;uas:egfp), expressed in trunk lymphatics, weak expression in PCV, with 
non-vascular expression in other organs, including lens, intestine and cardiac muscle 
[31]; Tg(-5.2lyve1b:egfp)nz150 and Tg(-5.2lyve1b:dsred)nz101, expressed in major axial 
veins and lymphatics, with weak non-vascular expression in fins [34]; the Tg(-
6.6flt4:YFP)hu488, with expression in DA, PCV and ISVs at 24 hpf, although expression 
becomes weak from 48 hpf [45]; the Tg(flt4BAC:mCitrine)hu7135, expressed in blood 
vessels initially and increasingly in venous from 26 hpf and by 5 dpf, with similar 
expression pattern to lyve1b) [56]; the 
Tg(prox1aBAC:KalTA4;4xUASE1b:unctagRFP)nim5, expressed in arterial and venous 
vessels before 24 hpf, although vascular expression becomes restricted to venous cells 
by 32 hpf and is lymphatic-specific by 5 dpf, with expression in a number of non-
vascular tissues such as the myotome, liver, neuromasts, lens and retina [57]; the 
Tg(prox1aBAC:Citrine)zf33, expressed in lymphatic vessels and lymphatic precursor cells 
on the posterior cardinal vein [34]. Lymphatic experimental assays in these transgenic 
lines primarily focus on the thoracic duct development, which can be quantified by 
counting the number of somites with thoracic duct or parachordal lymphangioblasts, 
and results can be represented as the developed or inhibited thoracic duct length. 
Another approach used with transgenic lines that express nuclear fluorophores under the 
fli1a promoter consists on the counting of LECs within the zebrafish thoracic duct [58]. 
Although the thoracic duct is regarded as the common site, additional lymphatic vessels, 
including a complex network of blind-ended lymphatic capillaries, can be identified in 
the zebrafish trunk using lymphangiography [41].    
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    Table S1. Antiangiogenic drugs approved by FDA/EMA for the treatment 
of solid tumors  
!
Drug% Type% Molecular%target% Malignancies%
Bevacizumab!
Humanized!
monoclonal!
antibody!
VEGF!
MCRC,!NSCLC,!OC,!MBC,!
glioblastoma,!metastatic!
RCC,!endometrial!cancer,!
mesothelioma!and!cervical!
cancers!
Ramucirumab!
Human!
monoclonal!
antibody!
VEGFR2! MCRC,!NSCLC,!gastric!adenocarcinoma!
Aflibercept!
(VEGFHTrap)!
Fusion!
protein!
(VEGFR!
chimera)!
VEGFHA/B,!
PlGF! MCRC!
Sunitinib! TKI! VEGFRH1H2,!!PDGFRσ/β!
Metastatic!RCC,!
gastrointestinal!stromal!
tumors,!pancreatic!
neuroendocrine!tumors!
Sorafenib! TKI! VEGFRH2,!!PDGFRβ!
Advanced!RCC,!
metastatic!differentiated!TC,!
unresectable!
HCC!
Pazopanib! TKI!
VEGFRH1H3,!!
PDGFRβ,!
FGFRH1H2!
Metastatic!STC!and!
advanced!RCC!
Vandetanib! TKI! VEGFRH2! Unresectable!or!metastatic!TC!
Axitinib! TKI! VEGFRH1H3,!!PDGFRβ! Advanced!RCC!
Regorafenib! TKI!
VEGFRH1H3,!!
PDGFRβ,!
FGFRH1H2!
ChemoHrefractory!MCRC,!
unresectable!HCC!and!GIST!
Cabozantinib! TKI! VEGFRH2,!Tie2!
Refractory!advanced!RCC,!
metastatic!
medullary!TC,!pancreatic!
neuroendocrine!
tumors!
Levantinib! TKI!
VEGFRH1H3,!!
PDGFRα,!
FGFRH1H4!
TC,!HCC!and!RCC!
Cediranib! TKI! VEGFRH1H3! OC!
TKI!(tyrosine!kinase!inhibitor),!MCRC!(Metastatic!colorectal!carcinoma),!NSCLC!(non!small!cell!
lung!cancer),!OC!(ovarian!cancer),!MBC!(metastatic!breast!cancer),!RCC!(renal!cell!carcinoma),!
HCC!(hepatocellular!carcinoma),!TC!(thyroid!carcinoma),!STC!(soft!tissue!carcinoma).!
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Table S2. Usage of endothelial-driven transgenic lines in reviewed articles 
        
Transgenic line Driving gen/expression ZFIN ref Supplier References 
Tg(fli1a:EGFP)y1 (y2-y5) Fli-1/Endothelial cells, cytoplasmic 888 Weinstein/ZIRC 1 
Tg(fli1:neGFP)y7 Fli-1/Endothelial cells, nuclear 107 Weinstein/ZIRC 2 
y1; Tg(lfabp:RFP; elaA:EGFP) Fli-1/liver fatty acid binding protein/pancreas elastase A/liver and exocrine pancreas 63 Gong lab/CZRC 3-5 
y1, Tg(elavl3:GCaMP5G)a4598 Fli-1/neural-specific RNA-binding protein/Neural specific- calcium indicator 30 Schier lab 6-8 
y1, Tg[lyve1:DsRed2/Flt1:YFP]nz150 Fli-1/Vegfc/Lymphatic-specific marker 4 (14/20) Crosier/Schulte-Merker/EZRC 9-11 
y1, Tg(NBT:MAPT-GFP)zc1 Fli-1/Microtubule-associated protein tau/Primary motor neuron marker 11 Chien lab 12 
y1, Tg(gata1:RFP)sd2 Fli-1/GATA-1/Endothelial cells and blood circulation 40 Zon lab 13-16 
Tg(gata1a:dsRed)sd2 GATA-1/Blood cells 201 EZRC-ZIRC 15, 17 
Tg(gata1:GFP)la781 GATA-1/Erythroid lineage 45 Shuo Lin lab 18 
Tg(gata2:eGFP)la3 GATA-2/Blood cells 6 Zon lab 17 
Tg(-7.8gata4:GFP)ae1 (ae2-3) GATA-4/Endocardial and myocardial cells 14 Evans lab 19-21 
Tg(0.8flt1:RFP)hu5333 Flt1/arterial ISV 20 Schulte-Merker lab 22 
Tg(efnb2a:EGFP)y77 Ligand of Eph-receptor/ Artery 1 Weinstein lab 23 
Tg(nkx2.3:efnb2a,myl7:EGFP)el589 Ligand of Eph-receptor/Artery 1 Crump lab 24 
Tg(dll4:EGFP)lcr1 Notch ligand/ Endothelial cells 1 De Val lab 25 
TgBAC(dll4:GAL4FF)hu10049 Notch ligand/Endothelial cells 2 Schulte-Merker lab 26 
Tg(hsp70l:canotch3-EGFP)co17 Notch3 intracellular domain/Perivascular 1 Appel lab 27 
TgPAC(tal1:d2eGFP)hkz08t Tal-1/Endothelial cells 2 Wen lab 28-29 
TgPAC(tal1:d2eGFP; tal1:DsRed)hkz06t Tal-1/Endothelial cells 1 Wen lab 28 
Tg(Tie2:eGFP)s849 Tie-2 receptor tyrosine kinase/Endothelial cells 20 Stainier lab 30-31 
Tg(5xUAS:cdh5-EGFP)ubs12 VE-cadherin/Pan-endothelial 7 Affolter Lab 32-34 
TgBAC(cdh5:Citrine)mu102 VE-cadherin/Pan-endothelial 2 Siekmann lab 35 
TgBAC(cdh5:GAL4FF)mu101 VE-cadherin/Pan-endothelial 8 Siekmann lab 22, 34 
Tg(kdrl:G-RCFP)zn1 (zn10) Vegfr2/flk1/kdr/Angioblast/endothelial precursors 53 Zygogene Research Department 36 
Tg(kdrl:RFP)la4 Vegfr2/flk1/kdr/Angioblast/endothelial precursors 14 Shuo Lin/CZRC 37 
Tg(kdrl:EGFP)s843 Vegfr2/flk1/kdr/Vegfr4/Angioblast/endothelial precursors 320 Stainier/CZRC,EZRC,ZIRC 38-39 
Tg(kdrl:nlsmCherry)is4 Vegfr2/flk1/kdr/Endothelial cells 6 Essner lab 40-42 
Tg(kdrl:mCherry)ci5 (is5) (fli1a:negfp)y1 
(y7) 
Fli-1,vegfr2/flk1/kdr/Endothelial marker, green nuclei 
and red cytoplam 3 (23/13) Sumanas/Essner labs 43-44 
TgBAC(flt4:Citrine)hu7135 Vegfr3/Pan-endothelial 7 Schulte-Merker lab 45-47 
Tg(flt4:YFP)hu4881 Vegfr3/Pan-endothelial 3 Schulte-Merker lab 48 
Tg(myl7:eGFP)twu277 Cardiac myosin light chain 2/Myocardial cells 193 Tsai lab 49-52 
Tg(myl7:Gal4-VP16)f15 Atrial myosin regulatory light chain 2/heart 2 Randal Patterson lab 53-54 
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Control
(DMSO) Genistein Kahweol  2-ME  MMF Sunitinib  SU4312
Intersegmental 
vessels - - ± + - + +
Videos - - + + - + +
Fin 
regeneration - ± + + - + +
Table S3. Results obtained with the tested compounds in three different zebrafish angiogenesis assays
Compound
Assay
(+) clear antiangiogenic effect; (-) clear non-antiangiogenic effect; (±) partial antiangiogenic effect
Intersegmental vessels assay Videos Fin regeneration assay
Advantages Disadvantages Advantages Disadvantages Advantages Disadvantages
•   Zebrafish embryos 
are an easy-
handling.
•   Since embryos are 
transparent, the 
visualization of the 
drug effects is 
easy.
 
•   It only requires 
small compound 
concentrations.  
•   This assay can be 
automated.!
•   It is a fast assay.
•   In few days, many 
embryos can be 
treated and many 
results can be 
obtained in a short 
time.
•   Although this 
assay is good for 
the identification of 
VEGF/VEGFR 
inhibitors, 
antiangiogenic 
compounds acting 
on different 
molecular targets  
may render false 
negatives .
•   Those derived 
from the use of 
zebrafish embryo.
•   It complements 
the information 
obtained with the 
intersegmental 
vessels assay. 
Sometimes, drugs 
do not inhibit 
vessel formation, 
but blood 
circulation through 
intersegmental 
vessels is 
compromised or 
abolished. These 
effects on blood 
circulation are 
easily observed in 
the movies.
•  Inadequate 
tricaine 
concentration 
used for zebrafish 
immovilization 
can affect the 
cardiac rate and 
the blood 
circulation 
through the 
intersegmental 
vessels.
•   This assay 
provides clear 
results, with low 
frequency of odd 
results.
•   It provides a 
better 
approximation to 
the toxicity of 
the tested 
reagents.
•   Use large 
working 
concentrations and 
subsequent agents 
quantity. This can 
be partially 
reduced if using 
juvenile zebrafish.
•   Absence of blood 
vessel formation is 
always associated 
to regeneration 
outgrowth arrest. 
This precludes any 
direct conclusion 
over angiogenesis.
Table S4.  Advantages and disadvantages observed in the three different zebrafish angiogenesis assays
Figure S1. The rise and fall of the use of different model species in research within the area of angiogenesis.?
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F	
D	
Compounds	
ISV	assay	
				Posi5ve/	
Total	
%	
inhibi5on	
DMSO	 1/50	 2	
Genistein	20	µM	 3/45	 6.7	
Kahweol	75	µM	 17/32	 53.1	
2-ME	10	µM	 25/30	 83.3	
MMF	50	µM	 1/35	 2.9	
Suni<nib	20	µM	 31/31	 100	
SU4312	20	µM	 30/30	 100	
Compounds	
Blood	circula5on	
movies	
				Posi5ve/	
Total	
%	
inhibi5on	
DMSO	 0/25	 0	
Genistein	20	µM	 8/24	 33.3	
Kahweol	75	µM	 13/20	 65	
2-ME	10	µM	 21/25	 84	
MMF	50	µM	 0/20	 0	
Suni<nib	20	µM	 22/22	 100	
SU4312	20	µM	 20/20	 100	
Compounds	
Caudal	ﬁn	
regenera5on	assay	
				Posi5ve/	
Total	
%	
inhibi5on	
DMSO	 0/5	 0	
Genistein	20	µM	 2/5	 40	
Kahweol	75	µM	 4/5	 80	
2-ME	10	µM	 4/5	 80	
MMF	50	µM	 0/5	 0	
Suni<nib	20	µM	 5/5	 100	
SU4312	20	µM	 5/5	 100	
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Supplementary figure legends 
Figure S1. The rise and fall of the use of different model species in research within the 
area of angiogenesis. Bibliometric search in Scopus were carried out using 
combinations of terms, such as <<angiogenesis>> and each model species including 
humans. The temporal evolution of the relative number of references is depicted. For 
each species, the number of references published in each year is relativized taking as 
relative value 1 the maximum number of articles published within a year. Asterisk 
indicates the years of the global economic crisis. 
Figure S2. Morphology of the embryonic tail bud and the caudal fin of the 
Tg(fli1a:EGFP)y1 zebrafish line. (A-B) Tail bud of 10 dpf (A) and 3 dpf (B) zebrafish 
embryos. The V-shaped muscle segments are the myomeres (A). (B) White and red 
arrows are intersegmental vessels and dorsal aorta, respectively. White and red 
arrowheads indicate dorsal longitudinal anastomotic vessel and caudal vein plexus, 
respectively. (C) Subintestinal vessels in a 3 dpf embryo (Reprinted from Journal of 
Ethnopharmacology, 151, Liu et al., Molecular mechanisms of angiogenesis effect of 
active sub-fraction from root of Rehmannia glutinosa by zebrafish sprout angiogenesis-
guided fractionation, 565–575., Copyright (2014), with permission from Elsevier). (D-
E) Embryonic thoracic duct (white arrowheads) after 4 days of incubation with DMSO 
(lymphagiogenesis analyses). (F-G) 0 (F) and 3 (G) dpa fin regenerates showing the 
formation of blood vessels in the fin blastema under DMSO treatment (G). White 
dashed line indicates amputation level. Bars represent 500 (A-B), 100 (D-E) and 150 (F-
G) µm. 
Figure S3. Three different assays to screen antiangiogenic compounds in zebrafish. (A) 
Intersegmental vessels assay in zebrafish embryos incubated with six different 
compounds and (B) table with the results obtained with each compound: 20 µM 
genistein do not inhibit the formation of intersegmental vessels, 75 µM kahweol slightly 
inhibits intersegmental vessels formation (arrows), 10 µM 2-methoxy-estradiol (ME) 
interrupts the growth of all the intersegmental vessels (arrows), 50 µM 
monomethlylfumarate (MMF) do not inhibit intersegmental vessels formation, 20 µM 
sunitinib removes all intersegmental vessels (bracket) and 20 µM SU4312 removes 
about seven caudal vessels (arrows). Bars represent 100 µm. Table shows the number of 
positive fishes over the total and the calculated percentage (% inhibition) affected by 
each treatment. (C) Embryonic regions observed in the videos and (D) table with the 
results obtained with the different compounds. Bars represent 50 in low and 150 µm in 
high magnification. (E) Photographs of fin cuts showing the effects of six compounds 
on the formation of blood vessels in the caudal fin regeneration assay and (F) table with 
the results of these assays: 20 µM genistein slightly inhibits vessels and fin 
regeneration, 5 µM kahweol completely inhibits blastema formation, 20 µM 2-ME 
significantly impairs blood vessel and 3 dpa blastema formation, 50 µM MMF does not 
inhibit either vessels formation or early caudal fin regeneration, 5 µM sunitinib 
completely suppresses blastema formation, and 5 µM SU4312 affects fin regeneration 
almost completely, and new blood vessels are not well formed. White dashed line 
indicates the cut level at 0 dpa. Bars represent 100 µm.  
Figures S4. This is a version of Figure 2 that contains the bibliographic references in 
which its contents is based. (A)! Table containing the information regarding the 
antiangiogenic activity exhibited by several angiogenesis inhibitors. (B) Scheme 
summarizing the results presented in the upper table. A free arrow indicates that 
compounds acting on a given target show a positive inhibition in a particular zebrafish-
based in vivo assay. A crossed arrow indicates that no antiangiogenic activity is 
detected by means of that assay. 
 
 
 
